Alpha Buying: Follow the Money From NVIDIA and Merck
Eikon Therapeutics Inc EIKN
$7.92
▼ -4.46%
($-0.37)
🔥 High Short Interest
Open
$8.45
Prev Close
$8.29
Day Range
$7.87 – $8.47
52W Range
$7.72 – $17.40
Market Cap
$428.99M
Beta
2.01
EPS (TTM)
$-10.10
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2026-02-05 |
| Shares Out. | 54,140,000 |
| Website | eikontx.com/ ↗ |
| Phone | 13026587581 |
| Employees | 384 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$88.4M |
| Total Assets | $779.6M |
| Total Liabilities | $313.1M |
| Equity | $466.5M |
About Eikon Therapeutics Inc
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.
Eikon Therapeutics Inc is a publicly traded company under the ticker symbol EIKN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-09-01)